CN102190622A - 依达拉奉的水溶性衍生物及其制备方法和应用 - Google Patents
依达拉奉的水溶性衍生物及其制备方法和应用 Download PDFInfo
- Publication number
- CN102190622A CN102190622A CN2010101242279A CN201010124227A CN102190622A CN 102190622 A CN102190622 A CN 102190622A CN 2010101242279 A CN2010101242279 A CN 2010101242279A CN 201010124227 A CN201010124227 A CN 201010124227A CN 102190622 A CN102190622 A CN 102190622A
- Authority
- CN
- China
- Prior art keywords
- edaravone
- organic solvent
- piperazine
- consumption
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical class O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 title claims abstract description 93
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 229950009041 edaravone Drugs 0.000 claims abstract description 80
- 150000001875 compounds Chemical class 0.000 claims abstract description 36
- -1 amino carbonic ether derivatives Chemical class 0.000 claims abstract description 25
- 230000002490 cerebral effect Effects 0.000 claims abstract description 17
- 241001465754 Metazoa Species 0.000 claims abstract description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000002253 acid Substances 0.000 claims abstract description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims abstract description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims abstract description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 3
- 125000000962 organic group Chemical group 0.000 claims abstract description 3
- 238000006243 chemical reaction Methods 0.000 claims description 39
- 239000003960 organic solvent Substances 0.000 claims description 39
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 38
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 33
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 claims description 17
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 15
- 150000004885 piperazines Chemical class 0.000 claims description 15
- 239000007924 injection Substances 0.000 claims description 14
- 238000002347 injection Methods 0.000 claims description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 11
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 11
- 239000003513 alkali Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 150000007530 organic bases Chemical class 0.000 claims description 11
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 claims description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 10
- 238000010189 synthetic method Methods 0.000 claims description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical class CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 8
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 7
- 230000006837 decompression Effects 0.000 claims description 7
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 7
- 235000010755 mineral Nutrition 0.000 claims description 7
- 239000011707 mineral Substances 0.000 claims description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- 239000003054 catalyst Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 6
- AKGSNUOZGBDODP-UHFFFAOYSA-N piperazine-1-carbonyl chloride Chemical class ClC(=O)N1CCNCC1 AKGSNUOZGBDODP-UHFFFAOYSA-N 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 150000002894 organic compounds Chemical class 0.000 claims description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical class CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 4
- 150000003222 pyridines Chemical class 0.000 claims description 4
- 150000003512 tertiary amines Chemical class 0.000 claims description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims description 4
- 229960000549 4-dimethylaminophenol Drugs 0.000 claims description 3
- 238000002425 crystallisation Methods 0.000 claims description 3
- 230000008025 crystallization Effects 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 125000002887 hydroxy group Chemical class [H]O* 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 2
- 235000017550 sodium carbonate Nutrition 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 239000012675 alcoholic extract Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 abstract description 3
- 230000002349 favourable effect Effects 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 27
- 206010008118 cerebral infarction Diseases 0.000 description 19
- 208000026106 cerebrovascular disease Diseases 0.000 description 15
- 239000007787 solid Substances 0.000 description 15
- 102000019197 Superoxide Dismutase Human genes 0.000 description 14
- 108010012715 Superoxide dismutase Proteins 0.000 description 14
- 210000004556 brain Anatomy 0.000 description 12
- 239000000706 filtrate Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- 239000012043 crude product Substances 0.000 description 6
- 238000001953 recrystallisation Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 206010061216 Infarction Diseases 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000007574 infarction Effects 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 4
- 201000006474 Brain Ischemia Diseases 0.000 description 4
- 206010008120 Cerebral ischaemia Diseases 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- OTCCIMWXFLJLIA-UHFFFAOYSA-N N-acetyl-DL-aspartic acid Natural products CC(=O)NC(C(O)=O)CC(O)=O OTCCIMWXFLJLIA-UHFFFAOYSA-N 0.000 description 3
- OTCCIMWXFLJLIA-BYPYZUCNSA-N N-acetyl-L-aspartic acid Chemical compound CC(=O)N[C@H](C(O)=O)CC(O)=O OTCCIMWXFLJLIA-BYPYZUCNSA-N 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
- 210000004004 carotid artery internal Anatomy 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- QUMRLXXCRQWODL-UHFFFAOYSA-N 1-methylpiperazin-1-ium;chloride Chemical compound [Cl-].C[NH+]1CCNCC1 QUMRLXXCRQWODL-UHFFFAOYSA-N 0.000 description 2
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 2
- 206010048962 Brain oedema Diseases 0.000 description 2
- 0 Cc(cc1OC(N2CCN(*)CC2)=O)n[n]1-c1ccccc1 Chemical compound Cc(cc1OC(N2CCN(*)CC2)=O)n[n]1-c1ccccc1 0.000 description 2
- 229940123457 Free radical scavenger Drugs 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- CTOUWUYDDUSBQE-UHFFFAOYSA-N benzyl piperazine-1-carboxylate Chemical compound C1CNCCN1C(=O)OCC1=CC=CC=C1 CTOUWUYDDUSBQE-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 208000006752 brain edema Diseases 0.000 description 2
- 210000001168 carotid artery common Anatomy 0.000 description 2
- 210000000269 carotid artery external Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- MSQACBWWAIBWIC-UHFFFAOYSA-N hydron;piperazine;chloride Chemical compound Cl.C1CNCCN1 MSQACBWWAIBWIC-UHFFFAOYSA-N 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000003447 ipsilateral effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 230000007971 neurological deficit Effects 0.000 description 2
- 238000011017 operating method Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- DNXXMYDADYAPDJ-UHFFFAOYSA-N 1-butylpiperazine;hydrochloride Chemical compound Cl.CCCCN1CCNCC1 DNXXMYDADYAPDJ-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- FXXMNCZOYVUJEE-UHFFFAOYSA-N C1(=CC=CC=C1)N1N=CCC1=O.CC1(CC(C(=O)O)=CC=C1)C(=O)O Chemical compound C1(=CC=CC=C1)N1N=CCC1=O.CC1(CC(C(=O)O)=CC=C1)C(=O)O FXXMNCZOYVUJEE-UHFFFAOYSA-N 0.000 description 1
- FBAIGEMWTOSCRU-UHFFFAOYSA-N CN(CC1)CCN1C(Cl)=O Chemical compound CN(CC1)CCN1C(Cl)=O FBAIGEMWTOSCRU-UHFFFAOYSA-N 0.000 description 1
- JZHWQCAOVXBGTH-UHFFFAOYSA-N CN(CC1)CCN1I Chemical compound CN(CC1)CCN1I JZHWQCAOVXBGTH-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 101800004637 Communis Proteins 0.000 description 1
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000016495 Horner Syndrome Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 238000006701 autoxidation reaction Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000003181 encephalopathic effect Effects 0.000 description 1
- 230000008753 endothelial function Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 229940079877 pyrogallol Drugs 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
组别 | 行为学评分 | SOD uv/mg pro | MDA nmol/mg pro |
假手术组 | 0 | 30.76±8.14 | 3.20±0.89 |
模型组 | 2.8±0.92 | 15.53±5.32 | 5.29±2.04 |
依达拉奉组 | 1.40±1.07** | 26.80±7.57** | 3.74±0.90* |
1组 | 1.6±0.78** | 27.23±7.64** | 3.63±0.90* |
2组 | 1.51±0.80** | 26.71±6.51** | 3.65±0.85* |
3组 | 1.70±O.95* | 25.55±738** | 3.68±0.88* |
4组 | 1.58±0.75** | 26.52±7.45** | 3.69±0.91* |
5组 | 1.62±0.83** | 27.15±6.83** | 3.70±0.87* |
6组 | 1.65±0.90** | 25.20±7.35** | 3.72±0.92* |
7组 | 2.00±0.85* | 25.17±6.02** | 3.77±1.26* |
8组 | 1.9±0.97* | 25.32±6.38** | 3.71±1.34* |
9组 | 1.73±0.80** | 26.32±7.35** | 3.75±0.85* |
10组 | 1.85±0.72** | 26.53±7.24** | 3.73±0.93* |
11组 | 1.65±1.10** | 25.65±6.83** | 3.76±0.92* |
12组 | 1.75±0.92** | 25.78±7.10** | 3.69±0.87* |
13组 | 1.83±0.87** | 26.31±6.95** | 3.65±0.90* |
14组 | 2.2±1.58** | 25.01±6.11** | 3.65±1.02* |
组别 | 脑梗塞指数(%) | 脑指数(%) |
假手术组 | 0 | 0.53±0.02 |
模型组 | 26.75±5.32 | 0.67±0.11 |
依达拉奉 | 14.44±3.27** | 0.58±0.06* |
1组 | 14.57±3.33** | 0.54±0.03* |
2组 | 14.30±3.40** | 0.55±0.04* |
3组 | 14.36±3.54** | 0.60±0.05* |
4组 | 14.50±3.20** | 0.55±0.06* |
5组 | 14.47±3.50** | 0.57±0.04* |
6组 | 14.80±3.67** | 0.59±0.03* |
7组 | 15.22±4.83* | 0.60±0.06 |
8组 | 15.86±3.42* | 0.55±0.04* |
9组 | 15.50±3.35** | 0.57±0.03* |
10组 | 15.30±3.40** | 0.58±0.01* |
11组 | 15.45±3.37** | 0.56±0.04* |
12组 | 15.63±3.15** | 0.58±0.02* |
13组 | 14.55±3.23** | 0.59±0.03* |
14组 | 15.40±3.19* | 0.54±0.03* |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010124227.9A CN102190622B (zh) | 2010-03-15 | 2010-03-15 | 依达拉奉的水溶性衍生物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010124227.9A CN102190622B (zh) | 2010-03-15 | 2010-03-15 | 依达拉奉的水溶性衍生物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102190622A true CN102190622A (zh) | 2011-09-21 |
CN102190622B CN102190622B (zh) | 2015-01-07 |
Family
ID=44599582
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201010124227.9A Active CN102190622B (zh) | 2010-03-15 | 2010-03-15 | 依达拉奉的水溶性衍生物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102190622B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102432663A (zh) * | 2011-10-27 | 2012-05-02 | 浙江工业大学 | 雷公藤红素衍生物及其制备和在治备抗肿瘤药物中的应用 |
KR20200031938A (ko) | 2018-09-17 | 2020-03-25 | 제이투에이치바이오텍 (주) | 에다라본 전구체 약물 화합물 및 이들의 신경퇴행성 또는 운동신경 질환의 치료 또는 개선을 위한 의약 용도 |
CN111793032A (zh) * | 2019-04-08 | 2020-10-20 | 四川省中医药科学院 | 一类吡唑啉酮类化合物及其制备方法和用途 |
WO2021107686A1 (ko) * | 2019-11-28 | 2021-06-03 | 제이투에이치바이오텍 주식회사 | 에다라본 전구체 약물 화합물 및 이들의 신경퇴행성 또는 운동신경 질환의 치료 또는 개선을 위한 의약 용도 |
JP2021534178A (ja) * | 2018-08-22 | 2021-12-09 | ジアンスー ヴァンガード ファーマシューティカル カンパニー,リミテッド | 置換ピラゾール類化合物、その調製方法、医薬組成物及び用途 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1493283A (zh) * | 2003-09-11 | 2004-05-05 | 彭建华 | 具有良好稳定性的注射用依达拉奉粉针剂及其制备方法 |
WO2006107771A2 (en) * | 2005-04-01 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | PYRAZOLO[3,4-c]QUINOLINES, PYRAZOLO[3,4-c]NAPHTHYRIDINES, ANALOGS THEREOF, AND METHODS |
CN1907954A (zh) * | 2006-08-16 | 2007-02-07 | 重庆医科大学医药研究所 | 麻醉药2,6-二异丙基苯酚的水溶性衍生物及其制备方法 |
CN101397301A (zh) * | 2008-09-10 | 2009-04-01 | 重庆医科大学医药研究所 | 含10-羟基喜树碱的水溶性衍生物及制备方法 |
-
2010
- 2010-03-15 CN CN201010124227.9A patent/CN102190622B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1493283A (zh) * | 2003-09-11 | 2004-05-05 | 彭建华 | 具有良好稳定性的注射用依达拉奉粉针剂及其制备方法 |
WO2006107771A2 (en) * | 2005-04-01 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | PYRAZOLO[3,4-c]QUINOLINES, PYRAZOLO[3,4-c]NAPHTHYRIDINES, ANALOGS THEREOF, AND METHODS |
CN1907954A (zh) * | 2006-08-16 | 2007-02-07 | 重庆医科大学医药研究所 | 麻醉药2,6-二异丙基苯酚的水溶性衍生物及其制备方法 |
CN101397301A (zh) * | 2008-09-10 | 2009-04-01 | 重庆医科大学医药研究所 | 含10-羟基喜树碱的水溶性衍生物及制备方法 |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102432663A (zh) * | 2011-10-27 | 2012-05-02 | 浙江工业大学 | 雷公藤红素衍生物及其制备和在治备抗肿瘤药物中的应用 |
CN102432663B (zh) * | 2011-10-27 | 2014-12-03 | 浙江工业大学 | 雷公藤红素衍生物及其制备和在制备抗肿瘤药物中的应用 |
JP7474744B2 (ja) | 2018-08-22 | 2024-04-25 | ジアンスー ヴァンガード ファーマシューティカル カンパニー,リミテッド | 置換ピラゾール類化合物、その調製方法、医薬組成物及び用途 |
JP2021534178A (ja) * | 2018-08-22 | 2021-12-09 | ジアンスー ヴァンガード ファーマシューティカル カンパニー,リミテッド | 置換ピラゾール類化合物、その調製方法、医薬組成物及び用途 |
KR20200031938A (ko) | 2018-09-17 | 2020-03-25 | 제이투에이치바이오텍 (주) | 에다라본 전구체 약물 화합물 및 이들의 신경퇴행성 또는 운동신경 질환의 치료 또는 개선을 위한 의약 용도 |
WO2020060092A1 (ko) | 2018-09-17 | 2020-03-26 | 제이투에이치바이오텍 주식회사 | 에다라본 전구체 약물 화합물 및 이들의 신경퇴행성 또는 운동신경 질환의 치료 또는 개선을 위한 의약 용도 |
CN112714760A (zh) * | 2018-09-17 | 2021-04-27 | J2H生物科技有限公司 | 依达拉奉前体药物化合物及其在治疗或改善神经退行性或运动神经元疾病中的医药用途 |
US11427547B2 (en) | 2018-09-17 | 2022-08-30 | J2H Biotech Inc. | Edaravone prodrug compound and pharmaceutical use thereof in treatment or alleviation of neurodegenerative or motor neuron disease |
KR102261931B1 (ko) | 2018-09-17 | 2021-06-07 | 제이투에이치바이오텍 (주) | 에다라본 전구체 약물 화합물 및 이들의 신경퇴행성 또는 운동신경 질환의 치료 또는 개선을 위한 의약 용도 |
CN111793032B (zh) * | 2019-04-08 | 2021-11-19 | 四川省中医药科学院 | 一类吡唑啉酮类化合物及其制备方法和用途 |
CN111793032A (zh) * | 2019-04-08 | 2020-10-20 | 四川省中医药科学院 | 一类吡唑啉酮类化合物及其制备方法和用途 |
KR20210067005A (ko) | 2019-11-28 | 2021-06-08 | 제이투에이치바이오텍 (주) | 에다라본 전구체 약물 화합물 및 이들의 신경퇴행성 또는 운동신경 질환의 치료 또는 개선을 위한 의약 용도 |
WO2021107686A1 (ko) * | 2019-11-28 | 2021-06-03 | 제이투에이치바이오텍 주식회사 | 에다라본 전구체 약물 화합물 및 이들의 신경퇴행성 또는 운동신경 질환의 치료 또는 개선을 위한 의약 용도 |
Also Published As
Publication number | Publication date |
---|---|
CN102190622B (zh) | 2015-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10525143B2 (en) | Conjugate of polyethylene glycol and anesthetic, and preparation method thereof | |
US11685739B2 (en) | High penetration drugs and their compositions thereof for treatment of Parkinson diseases | |
CN103221414B (zh) | 苯并二氮杂*衍生物的托西酸盐及其多晶型、它们的制备方法和用途 | |
CN102190622B (zh) | 依达拉奉的水溶性衍生物及其制备方法和应用 | |
US11999741B2 (en) | Process for the synthesis of 6-((3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-(tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one | |
CN101891728B (zh) | 灯盏乙素苷元衍生物及其制备方法和其应用 | |
EA027451B1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и их применение | |
ES2609264T3 (es) | Formas sólidas que comprenden (-)-O-desmetilvenlafaxina y usos de las mismas | |
CN103193789A (zh) | 一种光学活性的丁苯酞开环衍生物、制备方法及医药用途 | |
JP2020520949A (ja) | 組成物、並びにミトコンドリア脱共役剤を調製及び使用する方法 | |
CN114315585A (zh) | 一种羟戊苯甲酸双酯化合物及其制备方法和制药应用 | |
US6232331B1 (en) | Benzofuroxan derivatives, their therapeutic uses and pharmaceutical compositions | |
US20160244421A1 (en) | Derivative of Butylphthalide and Preparation Method and Use Thereof | |
WO2013168013A2 (en) | Compositions and methods for the treatment of chronic diseases and inflammatory disorders | |
TW201103911A (en) | Novel fumarate salts of a histamine H3 receptor antagonist | |
CN115991698A (zh) | 一种杂环化合物及其制备方法与应用 | |
ES2279100T3 (es) | Derivados de quinolina. | |
US9586925B2 (en) | 1-(dimethylamino)ethyl-substituted 6H-benzo[C]chromen-6-ones against senile dementia | |
CN107753469B (zh) | Ndga类似物在制备抗氧化药物中的应用 | |
US10519108B2 (en) | Inhibitors of retinaldehyde dehydrogenases and methods of use | |
JPH04368359A (ja) | カプサイシン誘導体又はその酸エステルを有効成分とする鎮痛剤、血管拡張剤 | |
WO2023046078A1 (zh) | 一种新型普拉洛芬衍生物及其药物组合物和用途 | |
CN112094255B (zh) | 一种灯盏花乙素苷元衍生物、其制备方法与应用 | |
WO2012121862A2 (en) | Valproic acid derivative compounds | |
WO2022166581A1 (zh) | 一种核苷酸衍生物及其药物组合物和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: ZHONGSHAN WANHAN PHARMATECH TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: LI QINGENG Effective date: 20150906 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150906 Address after: Guangdong city of Zhongshan province Southern China Nanlang 528451 modern Chinese Medicine City Branch Chong Park No. 2 Patentee after: Zhong Shanwanhan Pharmaceutical Technology Co., Ltd Address before: 400016 Institute of medicine, Medical University Of Chongqing, 1 Medical College Road, Yuzhong, Chongqing Patentee before: Li Qingeng |
|
CP01 | Change in the name or title of a patent holder |
Address after: Guangdong city of Zhongshan province Southern China Nanlang 528451 modern Chinese Medicine City Branch Chong Park No. 2 Patentee after: Zhongshan Wan Han Pharmaceutical Co., Ltd. Address before: Guangdong city of Zhongshan province Southern China Nanlang 528451 modern Chinese Medicine City Branch Chong Park No. 2 Patentee before: Zhong Shanwanhan Pharmaceutical Technology Co., Ltd |
|
CP01 | Change in the name or title of a patent holder |